米安舍林治疗脑卒中后抑郁症的临床研究

Clinical study of mianserin on post-stroke depression

目的评价米安舍林治疗脑卒中后抑郁症的临床疗效。方法入选我院住院的脑卒中后抑郁症患者100例,随机分成试验组和对照组,各50例。试验组口服米安舍林,初始剂量15 mg·d-1,1周后加至60 mg·d-1;对照组口服阿米替林,初始剂量30 mg·d-1,1周后加至150 mg·d-1,疗程均为8周。比较2组治疗前和治疗后的2,4,6,8周末的汉密尔顿抑郁量表(HAMD)、副反应量表(TESS)、日常生活指数(ADL)评分。结果试验组和对照组总有效率分别为86.0%和78.0%,差异无统计学意义(P>0.05)。2组患者治疗结束后HAMD评分均较治疗前显著下降,并且均随治疗时间延长逐步下降,但2组间差异无统计学意义(P>0.05)。2组患者的TESS评分在治疗各期差异均有统计学意义(P<0.01)。2组患者治疗结束后ADL评分均较治疗前显著升高(P<0.01)。结论米安舍林可较快缓解脑卒中后抑郁症患者的焦虑状况,并促进其功能有效康复。

Objective To evaluate the clinical efficacy of mianserin on post-stroke depression.Methods A total of 100 patients were random-ly selected and divided into treatment group （ 50 patients ） and control group （ 50 patients ） according to simple random sampling.Patients in treatment group were treated with mianserin （ the initial dose was 15 mg· d-1 , and 1 week later the dose was added to 60 mg· d-1 ） and those in control group with amitriptyline （ the initial dose was 30 mg· d-1 , and 1 week later the dose was added to 150 mg· d-1 ） .The data of hamilton depression scale（HAMD）, treatment emergent symptom scale（TESS） and activities of daily living（ADL） were assessed before treat-ment and 2, 4, 6 and 8 weeks after the treatment.Results The markedly effective rate in treatment group and control group were 86.0%and 78.0%, but the difference was not statistical different （ P 〉0.05 ） .The data of HAMD scores in two groups were both decreased compared with before treat-ment, but without statistical difference （P〉0.05）, the difference of TESS scores during the treatment were all significant in two groups （P〈0.01）. Conclusion Mianserin can relieve the anxiety of patients with post-stoke depression quickly and promote their function to be recovered effectively.